Read this topic

Every patient a vignette describes belongs in one of three bins with respect to a beta-blocker: an ABSOLUTE contraindication (the drug is genuinely dangerous right now), a CAUTION (use it, but watch more closely), or — the trap most candidates miss — an actual INDICATION that a nervous prescriber mistakes for a contraindication. Sorting a new patient into the correct bin, not reciting the list from memory, is what this concept actually tests.

For example, imagine two patients both labelled 'asthma' in their notes. One has not wheezed in three years and uses no inhaler; the other is wheezing audibly today and has needed a reliever four times this week. Both share the same word on the chart, but only one of them belongs in the absolute-contraindication bin — severity and timing decide the bin, not the label on the chart.

A beta-blocker works by occupying beta-adrenergic receptors so that circulating adrenaline and noradrenaline cannot act on them. Beta-1 receptors sit mainly in the heart: blocking them produces a chronotropic (heart-rate-slowing), dromotropic (conduction-slowing) and inotropic (contraction-force-reducing) effect — the basis of every cardiac contraindication on this list. Beta-2 receptors sit mainly in bronchial and peripheral vascular smooth muscle: blocking them removes bronchodilating tone, which is the airway danger, and can reduce peripheral blood flow, which underlies the vascular cautions.

A cardioselective agent such as bisoprolol blocks beta-1 receptors preferentially at low doses, which is why drug SELECTIVITY, not just the drug class 'beta-blocker', changes the risk calculus — a non-selective agent like propranolol carries a larger airway and peripheral-vascular risk than a cardioselective one at an equivalent cardiac dose.

One further mechanism explains the two hardest traps in this concept. A beta-blocker does not touch alpha-1 receptors at all. In a phaeochromocytoma — a catecholamine-secreting tumour, usually of the adrenal medulla — the tumour's output acts on both alpha- and beta-adrenergic receptors. Blocking only the beta receptors first removes beta-mediated vasodilation while leaving alpha-mediated vasoconstriction completely unopposed, which can precipitate a hypertensive crisis. This is why alpha-blockade (typically with phenoxybenzamine) always has to be established before a beta-blocker is added, never the other way round.

The second hard trap concerns hypoglycaemia. The adrenergic warning signs of low blood sugar — tachycardia and tremor — are produced through the same beta-adrenergic pathway a beta-blocker occupies, so they get masked. Sweating, however, is a cholinergically mediated response on a completely separate pathway, and is preserved. This is why hypoglycaemia unawareness in diabetes is a caution requiring closer glucose monitoring, not a reason to withhold the drug altogether.

Six pictures genuinely make beta-blockade dangerous right now: active bronchospasm (wheeze, recent exacerbation, heavy reliever use, especially on a non-selective agent); a second- or third-degree AV block with no pacemaker in place (a beta-blocker's negative dromotropic effect can tip an already-failing conduction system into complete heart block or asystole); severe, symptomatic bradycardia (no safety margin left for a drug that slows the heart further); cardiogenic shock (the heart is already failing to perfuse the body); acute decompensated heart failure (starting or increasing a beta-blocker can worsen an unstable heart in the short term); and a phaeochromocytoma with no alpha-blockade established yet.

Notice that four of these six are genuinely emergencies or near-emergencies on their own terms — cardiogenic shock and acute decompensation are dangerous regardless of any beta-blocker question. The beta-blocker question mainly sharpens around the airway, conduction and phaeochromocytoma pictures, which can otherwise look deceptively stable.

Five further pictures need closer monitoring rather than automatic avoidance: diabetes with hypoglycaemia unawareness (the classic, most heavily tested trap in this whole concept); severe peripheral arterial disease and Raynaud's phenomenon (both risk worsened peripheral vasospasm or reduced flow); Prinzmetal (variant) angina (a vasospastic, not purely atherosclerotic, cause of angina, where an unopposed alpha-vasoconstrictor effect from a non-selective agent can theoretically worsen the spasm); and mild, well-controlled airway disease managed on a cardioselective agent under specialist review, where severity, drug selectivity and oversight together make cautious use reasonable where active bronchospasm on a non-selective agent would not be.

The common thread across this whole bin is that none of these five is a reason to refuse the drug outright — each is a reason to prescribe carefully, choose the more selective agent where possible, and monitor for the specific harm each mechanism predicts.

Here is the fact that catches out even well-prepared candidates: stable chronic heart failure with reduced ejection fraction is not a contraindication to a beta-blocker at all. Bisoprolol, carvedilol and nebivolol are guideline-recommended, mortality-reducing treatments for this exact condition, once a patient is out of the acute decompensated phase. The caution genuinely applies only to the ACUTE, unstable state — not to heart failure as a label in general.

A candidate who has only memorised 'beta-blockers and heart failure don't mix' will wrongly flag a stable outpatient's guideline-appropriate bisoprolol as a problem to fix, when stopping it would remove a protective drug for no safety benefit whatsoever. This is precisely the kind of over-generalisation this whole concept is built to catch.

The BNF's monograph on beta-adrenoceptor blocking drugs is the reference this whole three-bin sort rests on — its contraindications, cautions and interactions entries are exactly what separates the absolute-stop bin from the caution bin above. In practice, managing a patient who needs a psychiatric beta-blocker (most often propranolol for tremor, akathisia, or performance anxiety) means working through the same three questions every time: is any comorbidity present ACUTE or quiet/stable right now; if a caution applies, would a more cardioselective agent at a lower starting dose reduce the risk while still treating the target symptom; and, for a patient already established on a beta-blocker for a chronic cardiac indication, is there any real reason to change that treatment, or is a psychiatric team about to undo a cardiology team's correct, evidence-based prescribing by mistake?

For a genuinely absolute contraindication, the beta-blocker is avoided and an alternative agent for the target symptom (for example, a benzodiazepine short-term for acute performance anxiety, or a dose reduction of the causative drug for tremor) is considered instead, with the reason documented clearly so the next prescriber does not have to re-derive it from scratch.

Before reading on, ask yourself what you would classify this as: if a vignette says 'diabetes' and nothing else, what is the correct classification — absolute contraindication, caution, or no problem at all? The correct answer is caution: monitor glucose more closely because the ADRENERGIC warning signs of hypoglycaemia are masked, while sweating is preserved through a different pathway, so hypoglycaemia can usually still be recognised, just less reliably.

Sort every comorbidity into absolute-stop, caution-and-monitor, or the reverse trap of an actual indication — by checking whether it is acute or stable, and which specific mechanism (airway, conduction, unopposed alpha, masked hypoglycaemia signs, or peripheral vasospasm) is really in play, never by the chart label alone.